Trial Profile
A phase III, multicenter, uncontrolled, open-label study to demonstrate safety and immunogenicity of a commercially available preservative free inactivated split influenza vaccine, using the strain composition 2006/2007 when administered to non-elderly adult and elderly subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jun 2011
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Chiron Vaccines; Novartis
- 10 Jul 2007 New trial record.